🇺🇸 FDA
Pipeline program

Briquilimab

JSP-CP-010

Phase 2 small_molecule terminated

Quick answer

Briquilimab for Chronic Inducible Urticaria is a Phase 2 program (small_molecule) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Jasper Therapeutics
Indication
Chronic Inducible Urticaria
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials